Loading…
Loading…
GILD · NASDAQ · Healthcare
“Most investors flee biotech complexity like cats from water, yet Gilead's moat deepens precisely because drug development requires both patience and brains.”
— In the voice of Munger
Evaluate financial health using Piotroski F-Score criteria — profitability, leverage, and operating efficiency metrics.
Market Cap
$175.30B
P/E Ratio
20.60
Forward P/E
—
EPS
$6.84
PEG Ratio
0.86
Book Value
$18.25
Dividend Yield
2.28%
Profit Margin
28.90%
ROE
37.48%
Use the interactive quality score with pre-loaded data for Gilead Sciences Inc. Adjust discount rates, growth assumptions, and projection horizons to model different scenarios.
Pre-loaded inputs for GILD: